PTC Therapeutics EVP, CLO Mark Elliott Boulding disposes 3,540 shares for $279,257.20

Ptc Therapeutics

Ptc Therapeutics

PTCT

0.00
  • Mark Elliott Boulding, executive vice president and chief legal officer, disclosed stock sales in PTC Therapeutics on May 8, 2026 under Rule 10b5-1 plan.
  • Sold 3,540 shares at weighted average prices of USD 78, USD 78.23, USD 79.28, USD 79.31.
  • Exercised options for 3,540 shares at USD 46.54.
  • Held 105,212 shares following transactions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000014), on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.